Xenetic Biosciences filings document the regulatory record for a Nasdaq-listed biopharmaceutical company developing DNase-based immuno-oncology technologies. Its Form 8-K reports cover operating and financial results, material events, capital-structure disclosures, equity incentive activity and governance matters tied to the company’s common stock.
Proxy materials describe annual meeting proposals, director elections, shareholder voting mechanics and board-related governance. The filing record also captures disclosures related to the company’s DNase program, collaboration activity, compensation arrangements, quorum and proxy-solicitation matters, and other formal updates affecting corporate reporting and stockholder approvals.
Xenetic Biosciences, Inc. amendment reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 137,440 shares of Common Stock, equal to 6.00% of the class. The filing notes certain funds managed by RTC have rights to dividends and sale proceeds.
Xenetic Biosciences reported first quarter 2026 results showing higher royalty revenue and a smaller loss while advancing its DNase oncology platform. Royalty revenue for the three months ended March 31, 2026 rose about 36% to approximately $0.8 million from about $0.6 million a year earlier, mainly from its sublicense with Takeda.
Research and development expenses fell to roughly $0.7 million and general and administrative expenses edged down to about $0.6 million, contributing to a reduced net loss of approximately $0.5 million versus about $0.9 million in 2025. The company ended the quarter with around $7.3 million in cash and continues to evaluate strategic alternatives while progressing translational research, investigator-initiated studies and manufacturing readiness for its DNase I immuno-oncology program.
Xenetic Biosciences, Inc. reported a smaller net loss for the quarter ended March 31, 2026 as royalty revenue increased. Royalty revenue rose to $806,923 from $593,261, while net loss narrowed to $456,382 from $903,141.
Operating expenses declined, with research and development and general and administrative costs both slightly lower than a year earlier. Cash was $7.3M and current liabilities about $1.0M, and the company believes existing resources can fund operations for at least twelve months, though additional capital will be needed longer term.
The company is conducting a formal strategic review, considering options including a sale, asset sale, or reverse merger that could leave counterparties’ investors holding a substantial majority of common stock. Xenetic continues to focus on advancing its DNase immuno-oncology technology and relies primarily on equity funding and royalties from its PolyXen license.
Xenetic Biosciences, Inc. filed an amendment to its annual report to add the Part III sections on directors, executive compensation, ownership and related-party transactions, and to update the cover-page share count to 2,291,056 common shares as of April 17, 2026. The filing details the board’s committee structure and independence, insider trading and related-party policies, and a single named executive officer, Interim CEO and CFO James Parslow. His 2025 total compensation was $536,027, including a $100,000 retention bonus and benefits, and he holds multiple option grants with exercise prices ranging from $3.88 to $548.40 per share. Pay-versus-performance tables show Compensation Actually Paid to the CEO moving broadly in line with total shareholder return and net losses, including a 2025 net loss of $2,680,860 and a total shareholder return value of $76.11 on a hypothetical $100 investment. The amendment also discloses 2025 audit and audit-related fees of $208,000, equity plan overhang of 115,622 options outstanding with 137,985 shares remaining available for issuance, and principal stockholders such as Renaissance Technologies LLC with 178,509 shares, or 7.8% of the common stock.
Xenetic Biosciences approved a new equity award for its Interim Chief Executive Officer and Chief Financial Officer, James Parslow, under its Amended and Restated Equity Incentive Plan. The grant consists of 100,000 shares of restricted stock, documented in a restricted stock award agreement dated April 21, 2026.
Of these shares, 7,000 vest immediately on the grant date. The remaining 93,000 shares will vest in three equal installments on each of the first, second, and third anniversaries of April 21, 2026. This structure is designed to tie Mr. Parslow’s compensation to ongoing service over several years.
PARSLOW JAMES F reported acquisition or exercise transactions in this Form 4 filing.
Xenetic Biosciences, Inc. reported that Interim CEO and CFO James F. Parslow received a grant of 100,000 shares of Common Stock as a restricted stock grant. The award was made at a stated price of $0.00 per share, indicating compensation rather than a market purchase.
According to the vesting terms, 7,000 shares vest on the grant date, and one-third of the remaining 93,000 shares will vest on each of the first, second, and third anniversaries of April 21, 2026. Following this grant, Parslow directly holds 100,000 shares of Xenetic Biosciences common stock.
Xenetic Biosciences reported a full-year 2025 net loss of approximately $2.7 million, as it continued investing in its DNase-based immuno-oncology programs targeting difficult-to-treat cancers. Royalty revenue from its sublicense with Takeda grew about 19% to $3.0 million, up from $2.5 million in 2024.
Research and development expenses were $3.1 million, down from $3.3 million, partly because a $0.7 million impairment recorded in 2024 did not recur, while DNase process development spending increased. General and administrative costs fell about 20% to $2.7 million. Xenetic ended 2025 with roughly $7.9 million in cash, about $1.7 million higher than the prior year, primarily from net proceeds of around $4.0 million raised in an October 2025 underwritten public offering.
Xenetic Biosciences is an early-stage immuno-oncology company focused on DNase technology to improve treatment of difficult solid tumors, initially pancreatic and colorectal cancers. The approach targets neutrophil extracellular traps that contribute to tumor growth and resistance to chemotherapy, radiotherapy and immunotherapy.
The company is advancing a systemic DNase I program toward first-in-human studies and exploring DNase‑armored CAR T cells to improve cell therapy performance in solid tumors. Development is executed largely through external partners and academic collaborations, including Scripps Research, the University of Virginia, Catalent and PeriNess.
Xenetic has begun a formal strategic review, considering options such as a sale, asset sale or reverse merger, with outcomes that could significantly alter ownership. The business remains unprofitable, expects substantial additional funding needs, and currently generates modest royalties from a PolyXen out‑license to Takeda while prioritizing DNase over legacy platforms.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed a Schedule 13G reporting beneficial ownership of 178,509 shares of Xenetic Biosciences, Inc. common stock, representing 7.79% of the outstanding class.
They report sole voting and dispositive power over all 178,509 shares, with no shared power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds. The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Xenetic Biosciences.
Xenetic Biosciences, Inc. reported that its 2025 Annual Meeting of Stockholders, originally adjourned from December 11, 2025 to January 8, 2026 to seek more proxies and achieve a quorum, was again adjourned on January 8, 2026 without any business being conducted because a sufficient number of shares was not represented.
The company plans to reconvene the Annual Meeting at a future date and time that has not yet been set and will give stockholders the required advance notice before the new meeting.